New UK SACT Board National Intrathecal and Intraventricular SACT Guidance

Dear colleagues,

We are pleased to share the newly published UK SACT Board National Guidance on the Safe Administration of Systemic Anti-Cancer Therapies via the Intrathecal or Intraventricular Routes.

This guidance represents an important national update to the arrangements for the safe delivery of intrathecal and intraventricular SACT. It replaces previous Department of Health national guidance and the relevant 2014 Manual for Cancer Services chemotherapy measures, reflecting developments in clinical practice, workforce models, governance and patient safety.

The guidance sets out expectations across governance, local policies, competency and training, prescribing, verification, dispensing, storage, issuing, checking and administration.

We would encourage all organisations delivering intrathecal or intraventricular SACT to review the guidance and consider its implications for their local policies, governance arrangements and clinical practice.

The guidance can be accessed here: UK SACT Board National Guidance

We would like to thank everyone who contributed to the development, consultation and review of this important piece of national guidance.

Please circulate this publication widely across relevant cancer, haematology, pharmacy, nursing, medical, governance and SACT teams.

UK SACT Board